Recent changes
- Aug 25, 2026Aug 25, 2026Two More S-1s Land: Enhanced Group, Serina Therapeutics Pulse story
- Aug 24, 2026Aug 24, 2026Serina Therapeutics Files to Sell Shares for Parkinson's Drug Pulse story
Latest Pulse
- Aug 28, 2026This Week's S-1 Filings by the NumbersAt least nine companies filed S-1 paperwork with the SEC this week, part of a pace that has produced roughly 39 US IPO pricings in the last five trading days alone.→
- Aug 25, 2026Two More S-1s Land: Enhanced Group, Serina TherapeuticsEnhanced Group filed a new S-1 on August 25 while biotech Serina Therapeutics registered up to 12.5 million shares for sale to Roth Principal Investments, two more entries in this week's dense small-cap SEC filing pipeline.→
- Aug 25, 2026Ocean Power Technologies Files S-1 for New OfferingOcean Power Technologies, a publicly traded wave-energy and marine-robotics company built around its PowerBuoy platform, filed a new S-1 registration with the SEC on August 25, 2026.→
- Aug 24, 2026Serina Therapeutics Files to Sell Shares for Parkinson's DrugBiotech Serina Therapeutics filed an S-1 covering up to 12.5 million shares tied to a stock purchase agreement, funding continued development of its lead Parkinson's disease candidate SER-252 built on its POZ drug-delivery platform.→
- Aug 24, 2026Five New S-1 Filings Show the IPO Window Stays OpenA fresh batch of SEC S-1 filings spanning energy, biotech and blank-check issuers shows smaller companies continuing to test the public market even as headline IPO attention stays on mega-cap listings.→
Coverage Timeline
newest firstAll Coverage
IPO
Two More S-1s Land: Enhanced Group, Serina Therapeutics
Enhanced Group filed a new S-1 on August 25 while biotech Serina Therapeutics registered up to 12.5 million shares for sale to Roth Principal Investments, two more entries in this week's dense small-cap SEC filing pipeline.
BY THE NUMBERS
Serina Therapeutics Files to Sell Shares for Parkinson's Drug
IPO
Serina Therapeutics Files to Sell Shares for Parkinson's Drug
Biotech Serina Therapeutics filed an S-1 covering up to 12.5 million shares tied to a stock purchase agreement, funding continued development of its lead Parkinson's disease candidate SER-252 built on its POZ drug-delivery platform.
DEEP DIVE